Vland Biotech(SH:603739)2024-04-25 09:43Financial Performance - The company's operating revenue for Q1 2024 was CNY 286,784,227.66, representing a year-on-year increase of 23.32%[2] - The net profit attributable to shareholders for the same period was CNY 12,722,943.82, up by 20.45% compared to the previous year[2] - Total revenue for Q1 2024 reached ¥286,784,227.66, an increase of 23.3% compared to ¥232,557,094.68 in Q1 2023[14] - Net profit for Q1 2024 was ¥17,162,518.08, up 36.5% from ¥12,552,054.99 in Q1 2023[15] - Operating profit for Q1 2024 was ¥22,637,992.14, representing a 54.3% increase from ¥14,686,668.71 in Q1 2023[15] - Basic and diluted earnings per share were both CNY 0.05, reflecting a 25.00% increase from the previous year[2] - Basic earnings per share for Q1 2024 were ¥0.05, up from ¥0.04 in Q1 2023[15] Cash Flow - The net cash flow from operating activities was negative at CNY -13,507,477.33, a decrease of 200.64% year-on-year, primarily due to increased payments for raw material purchases[6] - In Q1 2024, the net cash flow from operating activities was -$13.51 million, a decrease from $13.42 million in Q1 2023[18] - Cash inflow from operating activities was ¥317,112,598.93, compared to ¥302,820,693.88 in Q1 2023[17] - Total cash outflow from operating activities amounted to $330.62 million, compared to $289.40 million in the same period last year, reflecting a 14.3% increase[18] - The company reported a total cash outflow of $39.21 million for the quarter, compared to $26.02 million in the previous year[18] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 3,026,158,815.62, a slight decrease of 0.26% from the end of the previous year[2] - Total assets as of Q1 2024 were ¥3,026,158,815.62, slightly down from ¥3,034,057,625.33 in Q1 2023[12] - Total liabilities decreased to ¥1,185,326,125.90 from ¥1,208,671,719.25 in Q1 2023[12] - The total equity attributable to shareholders of the parent company was ¥1,722,773,343.78, an increase from ¥1,708,293,232.64 in Q1 2023[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,130[7] - The largest shareholder, Qingdao Kangdian Industrial Co., Ltd., held 44.42% of the shares[8] Research and Development - Research and development expenses increased to ¥26,717,261.31, up 17.9% from ¥22,660,128.74 in Q1 2023[14] Other Financial Metrics - The weighted average return on equity increased by 0.10 percentage points to 0.74%[2] - The company reported non-recurring gains and losses totaling CNY 9,106,615.85 for the quarter[5] - The company reported a decrease in other comprehensive income, with a net amount of -¥4,237.35 in Q1 2024 compared to -¥58,824.05 in Q1 2023[15] Cash Flow from Investment and Financing Activities - Cash inflow from investment activities was $17.75 million, significantly lower than $187.46 million in Q1 2023, indicating a decline of 90.5%[18] - The net cash flow from investment activities was -$64.98 million, an improvement from -$107.82 million in the previous year[18] - Cash inflow from financing activities totaled $129.96 million, up from $98.39 million in Q1 2023, representing a 32.0% increase[18] - The net cash flow from financing activities was $39.28 million, down from $68.38 million in the same quarter last year[18] - The ending cash and cash equivalents balance was $182.51 million, slightly up from $181.67 million in Q1 2023[18] Accounting Standards - The company did not adopt new accounting standards for the first quarter of 2024[19] Product Development and Market Strategy - The company did not disclose any new product developments or market expansion strategies during the quarter[9]